CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Imbruvica for Waldenström’s Macroglobulinemia - Details

Project Number PC0082-000
Brand Name Imbruvica
Generic Name Ibrutinib
Strength 140mg Capsules
Tumour Type Lymphoma
Indication Waldenstrom's Macroglobulinemia
Funding Request For the treatment of patients with Waldenström’s Macroglobulinemia who have received at least one prior therapy
Review Status Complete
Pre Noc Submission No
NOC Date March 31, 2016
Manufacturer Janssen Canada Inc.
Sponsor Janssen Canada Inc.
Submission Date April 21, 2016
Submission Deemed Complete April 28, 2016
Submission Type Initial
Prioritization Requested Not Requested
Stakeholder Input Deadline ‡ May 5, 2016
Check-point meeting June 23, 2016
pERC Meeting August 19, 2016
Clarification Please note that the August pERC meeting was conducted over two days. The original target date for the posting of pERC Initial Recommendation remains as September 1, 2016.
Initial Recommendation Issued September 1, 2016
Feedback Deadline ‡ September 16, 2016
pERC Reconsideration Meeting October 20, 2016
Final Recommendation Issued November 3, 2016
Notification to Implement Issued November 18, 2016
Therapeutic Area Waldenstrom's Macroglobulinemia
Recommendation Type Do not reimburse

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.